anti-doping comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-07-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
== Early life and education == Ochoa was born in Luarca (Asturias), Spain. His father was Severo Manuel Ochoa (who he was named after), a lawyer and businessman, and his mother was Carmen de Albornoz. Ochoa was the nephew of Álvaro de Albornoz (President of the Second Spanish Republic in exile and former Foreign Minister), and a cousin of the poet and critic Aurora de Albornoz. His father died when Ochoa was seven, and he and his mother moved to Málaga, where he attended elementary school through high school. His interest in biology was stimulated by the publications of the Spanish neurologist and Nobel laureate Santiago Ramón y Cajal. In 1923, he went to the University of Madrid Medical School, where he hoped to work with Ramón y Cajal, but Ramón y Cajal retired. He studied with father Pedro Arrupe, and Juan Negrín was his teacher:
=== 1980s === In March 1981, the CLP published the first issue of Rally, Comrades! as the "official organ of the Central Committee of the Communist Labor Party.” Its purpose was to "rally the ideological leaders of the workers in order to rally the workers for the final conflict.” Rally, Comrades! was circulated internationally. During the early 1980s, Rally, Comrades! published a series of articles analyzing and criticizing the political leaders of the Soviet Union. The Peoples Tribune and the Tribuno del Pueblo continued to be published by the CLP but spoke to a broader audience. All papers were bilingual (English and Spanish). With the economic recessions of the 1980s the CLP became active in labor union struggles against contract concessions and in aiding undocumented workers and the homeless. The CLP also participated in the mayoral campaigns of Harold Washington in Chicago and the Jesse Jackson run for the 1988 presidential election.
Apitoxin or bee venom is the venom produced by the honey bee. It is a cytotoxic and hemotoxic bitter colorless liquid containing proteins, which may produce local inflammation. It may have similarities to sea nettle toxin.
== Popular culture == In the 2013 biographical film Dallas Buyers Club, protagonist Ron Woodroof (Matthew McConaughey) promotes the use of injected peptide T as a treatment for HIV/AIDS and Alzheimer's disease and sues the FDA over their efforts to limit his ability to use peptide T, as it was an unapproved medicine. Additional information on Woodroof's court challenge to the FDA related to his obtaining access to peptide T can be found in the article by Marsha Cohen in Hastings Constitutional Law Quarterly (vol.18:471) [Cohen, 1991]. Woodroof's challenge was in part responsible for the 1987 revisions to the FDA investigational drug regulations that expanded access to experimental drugs for patients with serious diseases with no alternative therapies.
Accessory nail of the fifth toe Accessory tragus (ear tag, preauricular appendage, preauricular tag) Amniotic band syndrome (ADAM complex, amniotic band sequence, congenital constriction bands, pseudoainhum) Aplasia cutis congenita (cutis aplasia, congenital absence of skin, congenital scars) Arteriovenous fistula Benign neonatal hemangiomatosis Branchial cyst (branchial cleft cyst) Bronchogenic cyst Capillary hemangioma (infantile hemangioma, nevus maternus, strawberry hemangioma, strawberry nevus) Cavernous venous malformation Congenital cartilaginous rest of the neck (cervical accessory tragus, wattle) Congenital erosive and vesicular dermatosis Congenital hypertrophy of the lateral fold of the hallux Congenital lip pit (congenital sinus of the lower lip, lip sinus, midline sinus of the upper lip) Congenital malformations of the dermatoglyphs Congenital smooth muscle hamartoma Cystic lymphatic malformation Dermoid cyst Diffuse neonatal hemangiomatosis Encephalocele Familial disseminated comedones without dyskeratosis Focal facial dermal dysplasia Hutchinson's teeth Hyperkeratotic cutaneous capillary-venous malformation Intrauterine epidermal necrosis Limb–mammary syndrome Lowry–MacLean syndrome Macrocheilia Macrocystic lymphatic malformation Malignant pilomatricoma (pilomatrical carcinoma, pilomatrix carcinoma) Maternal autoimmune bullous disease Median raphe cyst Melanotic neuroectodermal tumor of infancy Membranous aplasia cutis Microcystic lymphatic malformation Midline cervical cleft Mongolian spot (congenital dermal melanocytosis, dermal melanocytosis) Mulberry molar Nager acrofacial dysostosis Nasal glioma (brain-like heterotopia, cephalic brain-like heterotopia, glial hamartoma, heterotopic neuroglial tissue, nasal cerebral heterotopia, nasal heterotopic brain tissue) Nasolacrimal duct cyst Nevus psiloliparus Non-involuting congenital hemangioma Omphalomesenteric duct cyst (omphalomesenteric duct remnant, vitelline cyst) PELVIS syndrome Pilomatricoma (calcifying epithelioma of Malherbe, Malherbe calcifying epithelioma, pilomatrixoma) Poland anomaly Posterior fossa malformations–hemangiomas–arterial anomalies–cardiac defects–eye abnormalities–sternal cleft and supraumbilical raphe syndrome (PHACE association, PHACES syndrome) Preauricular sinus and cyst (ear pit, congenital auricular fistula, congenital preauricular fistula, preauricular cyst) Rapidly involuting congenital hemangioma (congenital nonprogressive hemangioma) Rosenthal–Kloepfer syndrome Rudimentary supernumerary digit (rudimentary polydactyly) SACRAL syndrome Sinus pericranii Skin dimple (skin fossa) Superficial lymphatic malformation (lymphangioma circumscriptum) Supernumerary nipple (accessory nipple, pseudomamma) Thyroglossal duct cyst Verrucous vascular malformation (angiokeratoma circumscriptum naeviforme)
Sources: en.wikipedia.org
== Safety == Most of the available einsteinium toxicity data is from research on animals. Upon ingestion by rats, only ~0.01% of it ends in the bloodstream. From there, about 65% goes to the bones, where it would remain for ~50 years if not for its radioactive decay, not to speak of the three-year maximum lifespan of rats, 25% to the lungs (biological half-life ~20 years, though this is again rendered irrelevant by the short half-life of einsteinium), 0.035% to the testicles or 0.01% to the ovaries—where einsteinium stays indefinitely. About 10% of the ingested amount is excreted. The distribution of einsteinium over bone surfaces is uniform and is similar to that of plutonium.
=== PIDDosome === PIDD-CC serves as a nucleating agent for the assembly of a complex with the dual adaptor protein RAIDD, which plays a pivotal role in the recruitment and activation of CASP2, potentially triggering apoptotic pathways. This assembly is widely recognized as the PIDDosome. In contrast, signaling pathways involving PIDD-C are primarily linked to the activation of NF-κB, thereby enhancing cell survival. In response to DNA damage, PIDD-C undergoes translocation to the nucleus, where it forms a complex with RIP1 and the NF-κB essential modulator (NEMO, also known as IKBKG), collectively termed the NEMO-PIDDosome. The term "PIDDosome" is commonly used to refer to a multiprotein complex that is made up of p53-induced death domain protein 1 (PIDD1), the bipartite linker protein CRADD (also known as RAIDD), and the inactive precursor of the caspase family endopeptidase, called caspase-2.
== Scoville organoleptic test == In the Scoville organoleptic test, an exact weight of dried pepper is dissolved in alcohol to extract the heat components (capsaicinoids), then diluted in a solution of sugar water. Decreasing concentrations of the extracted capsaicinoids are given to a panel of five trained tasters, until a majority (at least three) can no longer detect the heat in a dilution. The heat level is based on this dilution, rated in multiples of 100 SHU. Another source using subjective assessment stated, "Conventional methods used in determining the level of pungency or capsaicin concentration are using a panel of tasters (Scoville organoleptic test method). ... Pepper pungency is measured in Scoville heat units (SHU). This measurement is the highest dilution of a chili pepper extract at which heat can be detected by a taste panel." A weakness of the Scoville organoleptic test is its imprecision due to human subjectivity, depending on the taster's palate and number of mouth heat receptors, which vary widely among subjects. Another shortcoming is sensory fatigue; the palate is quickly desensitized to capsaicinoids after tasting a few samples within a short time period. Results vary widely (up to ± 50%) between laboratories.
When the process is applied to food and the water is evaporated and removed, the food can be stored for long periods without spoiling. It is also used when boiling a substance at normal temperatures would chemically change the consistency of the product, such as egg whites coagulating when attempting to dehydrate the albumen into a powder. This process was invented by Henri Nestlé in 1866, of Nestlé Chocolate fame, although the Shakers were already using a vacuum pan before that (see condensed milk). This process is used industrially to make such food products as evaporated milk for milk chocolate and tomato paste for ketchup.
=== Insulin biosynthesis and transcription === Insulin biosynthesis is regulated by transcriptional and translational levels. The β-cells promote their protein transcription in response to nutrients. The exposure of rat Langerhans islets to glucose for 1 hour is able to remarkably induce the intracellular proinsulin levels. It was noted that the proinsulin mRNA remained stable. This suggests that the acute response to glucose of the insulin synthesis is independent of mRNA synthesis in the first 45 minutes because the blockage of the transcription decelerated the insulin accumulation during that time. PTBPs, also called polypyrimidine tract binding proteins, are proteins that regulate the translation of mRNA. They increase the viability of mRNA and provoke the initiation of the translation. PTBP1 enable the insulin gene-specific activation and insulin granule protein mRNA by glucose. Two aspects of the transduction pathway process are explained below: insulin secretion and insulin action on the cell.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.